sb 216763 and su 11248
sb 216763 has been researched along with su 11248 in 2 studies
Compound Research Comparison
Studies (sb 216763) | Trials (sb 216763) | Recent Studies (post-2010) (sb 216763) | Studies (su 11248) | Trials (su 11248) | Recent Studies (post-2010) (su 11248) |
---|---|---|---|---|---|
342 | 0 | 225 | 4,338 | 560 | 3,200 |
Protein Interaction Comparison
Research
Studies (2)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 1 (50.00) | 2.80 |
Authors
Authors | Studies |
---|---|
Chu, Y; Gao, Y; Huang, K; Li, S; Li, X; Lu, W; Ye, D; Zhang, P | 1 |
Ishida, T; Itoh, T; Nishigori, C; Omura, T; Sakane, T; Yamamoto, K; Yano, I; Yoshida, A | 1 |
Other Studies
2 other study(ies) available for sb 216763 and su 11248
Article | Year |
---|---|
Novel benzothiazinones (BTOs) as allosteric modulator or substrate competitive inhibitor of glycogen synthase kinase 3β (GSK-3β) with cellular activity of promoting glucose uptake.
Topics: 3T3-L1 Cells; Allosteric Regulation; Animals; Benzothiazoles; Binding Sites; Binding, Competitive; Biological Transport; Glucose; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Hep G2 Cells; Humans; Kinetics; Mice; Molecular Docking Simulation; Protein Binding; Protein Kinase Inhibitors; Protein Structure, Tertiary; Substrate Specificity | 2014 |
Sunitinib decreases the expression of KRT6A and SERPINB1 in 3D human epidermal models.
Topics: Antineoplastic Agents; Cell Line; Epidermis; Gene Expression; Humans; Indoles; Keratin-5; Keratin-6; Maleimides; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phosphorylation; Serine Peptidase Inhibitors, Kazal Type; Serpins; Sunitinib | 2021 |